

## [Cisplatin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XA01](#)

Indication

Malignant neoplasms of hypopharynx ICD11 code: [2B6D](#)

INN

Cisplatin

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 50 mg per 50 mL ; 100 mg per 100 mL ; 10 mg per 10 mL ; 20 mg per 20 mL

EML status history

First added in 1984 ([TRS 722](#))

Changed in 2015 ([TRS 994](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Cisplatin](#)

[DrugBank](#)

[Cisplatin](#)

Summary of evidence and Expert Committee recommendations



The Expert Committee recommended the addition of new strength formulations of cisplatin IV injection (10 mg/10 mL and 20 mg/20 mL) to the EML.